From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fomivirsen composite.png
Clinical data
AHFS/ Micromedex Detailed Consumer Information
Pregnancy cat.
Legal status
Routes Intravitreal injection
CAS number 160369-77-7 YesY
ATC code S01AD08
KEGG D02736 YesY
Chemical data
Formula C204H263N63O114P20S20 
Mol. mass 6682.4 g/mol
 N (what is this?)  (verify)

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was licenced by the FDA for CMV in Aug 1998.

It is a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:



It is an oligonucleotide[1] that blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.[2]


It is available as an intraocular injection in a concentration of 6.6 mg/mL.[3]

See also[edit]


  1. ^ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMC 105584. PMID 9559825. 
  2. ^ Roush W (May 1997). "Antisense aims for a renaissance". Science 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327. 
  3. ^ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. p. 817. ISBN 0-07-145153-6. 

Further reading[edit]

  • Grillone, LR; Lanz, R (2001). "Fomivirsen". Drugs Today (Barc) 37 (4): 245–255. PMID 12768225. 
  • Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clin Pharmacokinet 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144. 
  • Vitravene Study, Group (2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". Am J Ophthalmol 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781. 
  • Roehr B (1998). "Fomivirsen approved for CMV retinitis". J Int Assoc Physicians AIDS Care 4 (10): 14–6. PMID 11365956. 

External links[edit]